Chirattikan MaicheenWeerasak SameeJiraporn UngwitayatornMahidol UniversitySrinakharinwirot University2018-12-212019-03-142018-12-212019-03-142017-10-01Chiang Mai Journal of Science. Vol.44, No.4 (2017), 1395-1406012525262-s2.0-85030712046https://repository.li.mahidol.ac.th/handle/20.500.14594/41756© 2017, Chiang Mai University. All rights reserved. HIV-1 reverse transcriptase (HIV-1 RT) still remains an important target in the investigation of anti-HIV drugs. A series of synthesized phthalimide derivatives have been previously evaluated for their HIV-1 RT inhibitory activity. In this study, phthalimide derivatives were subjected to docking study against 6 X-ray crystal structures of wild-type HIV-1 RT using AutoDock software. Docking results revealed that these phthalimide compounds bound in a similar position and orientation as the clinically used non-nucleoside RT inhibitor (NNRTI), nevirapine. The bound conformations of the 3 most potent compounds, 11, 25, and 29 with HIV-1 RT were in a roof-like shape, the 3-dimensional pharmacophore for NNRTI proposed by Schäfer et al. Moreover, the potent phthalimides showed the comparable binding affinity to nevirapine toward the enzyme.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyChemistryMolecular docking study of phthalimide derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitorArticleSCOPUS